Ryuichi Mizuno

6.2k total citations
205 papers, 2.6k citations indexed

About

Ryuichi Mizuno is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Ryuichi Mizuno has authored 205 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Pulmonary and Respiratory Medicine, 69 papers in Surgery and 57 papers in Oncology. Recurrent topics in Ryuichi Mizuno's work include Renal cell carcinoma treatment (65 papers), Bladder and Urothelial Cancer Treatments (51 papers) and Prostate Cancer Diagnosis and Treatment (36 papers). Ryuichi Mizuno is often cited by papers focused on Renal cell carcinoma treatment (65 papers), Bladder and Urothelial Cancer Treatments (51 papers) and Prostate Cancer Diagnosis and Treatment (36 papers). Ryuichi Mizuno collaborates with scholars based in Japan, United States and United Kingdom. Ryuichi Mizuno's co-authors include Mototsugu Oya, Shuji Mikami, Takeo Kosaka, Masaru Murai, Eiji Kikuchi, Yasunori Okada, Ken Marumo, Akira Miyajima, Toshiaki Shinojima and Nobuyuki Tanaka and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The EMBO Journal.

In The Last Decade

Ryuichi Mizuno

191 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ryuichi Mizuno Japan 28 1.2k 1.1k 926 526 509 205 2.6k
Tomomi Kamba Japan 27 1.2k 1.0× 1.3k 1.3× 1.0k 1.1× 635 1.2× 371 0.7× 152 3.3k
Alessia Cimadamore Italy 26 1.3k 1.1× 841 0.8× 877 0.9× 577 1.1× 824 1.6× 147 2.6k
Bo Dai China 32 1.3k 1.1× 1.4k 1.3× 1.1k 1.2× 1.0k 1.9× 639 1.3× 144 3.3k
Simon J. Crabb United Kingdom 28 716 0.6× 1.2k 1.1× 1.2k 1.3× 487 0.9× 938 1.8× 137 3.0k
Noboru Nakaigawa Japan 30 1.5k 1.3× 1.8k 1.7× 719 0.8× 734 1.4× 475 0.9× 127 3.3k
Yang Yao China 29 1.1k 0.9× 694 0.7× 1.2k 1.3× 302 0.6× 333 0.7× 125 2.4k
Veronica Mollica Italy 29 1.6k 1.3× 853 0.8× 1.5k 1.6× 620 1.2× 691 1.4× 155 3.0k
Badar M. Mian United States 21 840 0.7× 718 0.7× 521 0.6× 340 0.6× 390 0.8× 60 1.9k
Dingwei Ye China 29 1.0k 0.9× 1.1k 1.1× 501 0.5× 874 1.7× 401 0.8× 114 2.3k
Giuseppe Floris Belgium 28 670 0.6× 793 0.7× 1.1k 1.2× 642 1.2× 274 0.5× 118 2.6k

Countries citing papers authored by Ryuichi Mizuno

Since Specialization
Citations

This map shows the geographic impact of Ryuichi Mizuno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryuichi Mizuno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryuichi Mizuno more than expected).

Fields of papers citing papers by Ryuichi Mizuno

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryuichi Mizuno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryuichi Mizuno. The network helps show where Ryuichi Mizuno may publish in the future.

Co-authorship network of co-authors of Ryuichi Mizuno

This figure shows the co-authorship network connecting the top 25 collaborators of Ryuichi Mizuno. A scholar is included among the top collaborators of Ryuichi Mizuno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryuichi Mizuno. Ryuichi Mizuno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kondoh, Chihiro, Woo Kyun Bae, Satoshi Tamada, et al.. (2025). First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern Asia. Japanese Journal of Clinical Oncology. 55(4). 406–413. 2 indexed citations
2.
Kato, Taigo, Junya Furukawa, Nobuyuki Hinata, et al.. (2024). Real-world outcomes of avelumab plus axitinib in patients with advanced renal cell carcinoma in Japan: long-term follow-up from the J-DART2 retrospective study. International Journal of Clinical Oncology. 30(1). 99–109. 2 indexed citations
3.
Kikuchi, Eiji, Hiroyuki Yamamoto, Takahiro Yasui, et al.. (2024). The first detailed annual record on the National Clinical Database Urology Division in Japan: A report on five surgical procedures. International Journal of Urology. 31(12). 1344–1355. 4 indexed citations
4.
Saito, Takafumi, Kent Kanao, Takayuki Takahashi, et al.. (2023). New risk stratification for adjuvant nivolumab for high‐risk muscle‐invasive urothelial carcinoma. SHILAP Revista de lepidopterología. 5(2). 281–288. 1 indexed citations
5.
Hasegawa, Masanori, Takahiro Ogawa, Masayoshi Kawakami, et al.. (2023). Impact of tumor contact surface area on collecting system entry in robot-assisted partial nephrectomy: a retrospective analysis. BMC Urology. 23(1). 85–85. 2 indexed citations
6.
Shimozaki, Keitaro, Kenro Hirata, Yukie Hayashi, et al.. (2021). The Entire Intestinal Tract Surveillance Using Capsule Endoscopy after Immune Checkpoint Inhibitor Administration: A Prospective Observational Study. Diagnostics. 11(3). 543–543. 2 indexed citations
7.
Kikuchi, Eiji, Koichiro Ogihara, Keisuke Shigeta, et al.. (2021). Role of Previous Malignancy History in Clinical Outcomes in Patients with Initially Diagnosed Non-Muscle Invasive Bladder Cancer. Annals of Surgical Oncology. 28(9). 5349–5359. 4 indexed citations
8.
Kondoh, Chihiro, Woo Kyun Bae, Satoshi Tamada, et al.. (2020). 200O Pembrolizumab plus axitinib (pembro + axi) vs sunitinib in metastatic renal cell carcinoma (mRCC) outcomes of the KEYNOTE-426 study in patients from eastern Asia. Annals of Oncology. 31. S1319–S1319. 3 indexed citations
9.
10.
Shimozaki, Keitaro, Yasutaka Sukawa, Isao Kurihara, et al.. (2020). <p>Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors</p>. Cancer Management and Research. Volume 12. 4585–4593. 57 indexed citations
11.
12.
Niwa, Naoya, Nobuyuki Tanaka, Hiroshi Hongo, et al.. (2019). TNFAIP2 expression induces epithelial-to-mesenchymal transition and confers platinum resistance in urothelial cancer cells. Laboratory Investigation. 99(11). 1702–1713. 20 indexed citations
13.
Takamatsu, Kimiharu, Ryuichi Mizuno, Shinya Morita, et al.. (2018). Prognostic Value of Baseline Serum C-Reactive Protein Level in Intermediate-Risk Group Patients With Metastatic Renal-Cell Carcinoma Treated by First-Line Vascular Endothelial Growth Factor–Targeted Therapy. Clinical Genitourinary Cancer. 16(4). e927–e933. 20 indexed citations
14.
Kosaka, Takeo, Shuji Mikami, Ari Hashimoto, et al.. (2017). 上部尿路尿路上皮癌における赤血球蛋白質バンド4.1like5発現の予後的意義【Powered by NICT】. Urologic Oncology Seminars and Original Investigations. 35(9). 17–543. 1 indexed citations
15.
Mizuno, Ryuichi, Akira Miyajima, Taizo Hibi, et al.. (2017). Impact of baseline visceral fat accumulation on prognosis in patients with metastatic renal cell carcinoma treated with systemic therapy. Medical Oncology. 34(4). 47–47. 17 indexed citations
16.
Tanaka, Nobuyuki, Ryuichi Mizuno, Keiichi Ito, et al.. (2015). External Validation of the MSKCC and IMDC Risk Models in Patients Treated with Targeted Therapy as a First-line and Subsequent Second-line Treatment: A Japanese Multi-institutional Study. European Urology Focus. 2(3). 303–309. 25 indexed citations
17.
Shinojima, Toshiaki, Qiang Yu, Sharon K. Huang, et al.. (2012). Heterogeneous epigenetic regulation ofTIMP3in prostate cancer. Epigenetics. 7(11). 1279–1289. 32 indexed citations
18.
19.
Mizuno, Ryuichi, Jun Nakashima, Makio Mukai, et al.. (2009). Tumour length of the largest focus predicts prostate‐specific antigen‐based recurrence after radical prostatectomy in clinically localized prostate cancer. British Journal of Urology. 104(9). 1215–1218. 24 indexed citations
20.
Oya, Mototsugu, Atsushi Takayanagi, Akio Horiguchi, et al.. (2003). Increased nuclear factor-κB activation is related to the tumor development of renal cell carcinoma. Carcinogenesis. 24(3). 377–384. 103 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tomomi Kamba Breakdown of academic impact, for papers by Alessia Cimadamore Breakdown of academic impact, for papers by Bo Dai Breakdown of academic impact, for papers by Simon J. Crabb Breakdown of academic impact, for papers by Noboru Nakaigawa Breakdown of academic impact, for papers by Yang Yao Breakdown of academic impact, for papers by Veronica Mollica Breakdown of academic impact, for papers by Badar M. Mian Breakdown of academic impact, for papers by Dingwei Ye Breakdown of academic impact, for papers by Giuseppe Floris
Rankless by CCL
2026